Moderna, combined COVID/flu vaccine better than separate shots

Moderna combined COVIDflu vaccine better than separate shots

(Finance) – Moderna biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines, announced that its Phase 3 study of mRNA-1083, a experimental combined vaccine against influenza and COVID-19, met its primary endpoints, eliciting a higher immune response compared to authorized comparator vaccines.

“Combination vaccines have the potential to reduce the burden of respiratory viruses on healthcare systems and pharmaciesas well as offering people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal diseases – said the CEO Stéphane Bancel – Moderna is the only company with a positive Phase 3 combination vaccine against influenza and COVID.”

mRNA-1083 includes components of mRNA-1010Moderna’s seasonal flu vaccine candidate, and mRNA-1283, Moderna’s next-generation COVID-19 vaccine candidate. Each experimental vaccine has independently demonstrated positive results in Phase 3 clinical trials.